During the COVID-19 crisis, as hospitals filled and unemployment soared, a handful of well-connected corporations and insiders reaped staggering profits.
Critics have dubbed these big winners “pandemic profiteers,”warning that their gains came at the expense of the public interest. As one watchdog put it, “a handful of corporations are raking it in and making already rich shareholders even richer” while tens of millions of Americans lost jobs.
Our investigation traces how emergency contracts and deals—at both the federal and state level—were funneled to favored firms in pharmaceuticals, medical supplies, logistics, defense and tech. We show how lobbyists and insiders lined up billions in no-bid contracts, even as small businesses and the public paid the price.
Real numbers, charts, and whistleblower testimony reveal a pattern of bias and waste in the pandemic procurement process. From Washington to London, Brasília to Delhi, the same stories play out: opaque deals, political connections, and unchecked greed.
President Donald Trump announces Operation Warp Speed at the White House in May 2020, promising an unprecedented sprint toward a vaccine.
But behind the scenes, trillions in COVID relief were being handed out without normal safeguards. Federal spending on pandemic response eventually topped $5 trillion, yet oversight often lagged.
A report by Public Citizen and the Center for Responsive Politics found that in 2020 just 6% of companies winning COVID-related federal contracts got over half the money (over $19 billion).
In fact, 2% of contractors who lobbied on coronavirus issues captured 37% of all contract dollars (about $13.4 billion).
These lobbied firms deployed over 3,500 lobbyists in 2020 and threw $313 million in campaign contributions at lawmakers and Trump aides.
As one analyst warned, “vendors were far more likely to be chosen if they supplemented their offers of assistance with visits from their lobbyists”.
In short, amid the pandemic panic, government contracts flowed not to the most capable suppliers but to those with the right political ties.
The scale of inequality underscored these imbalances. In April 2020, the official U.S. unemployment rate exploded to 14.7%, a postwar record.
At the same time the stock market rebounded dramatically (the S&P 500 roughly doubling from its March trough to year-end 2020), billionaire wealth exploded.
One analysis found that between March and June 2020 the roughly 640 U.S. billionaires saw their combined net worth jump by $584 billion (20%), even as 45.5 million Americans filed unemployment claims.
By early 2024 there were 737 U.S. billionaires worth $5.529 trillion—an 87.6% jump since the pandemic began.
As the Institute for Policy Studies noted, in that first spring of the pandemic billionaires’ wealth grew twice as fast as the $800 stimulus checks paid to 150 million Americans.
“We have to be careful about what we throw out” in the rush to contract, cautioned a legal scholar—but in 2020 many traditional rules were abandoned.
The result was what some called a K-shaped recovery: Wall Street and corporate boards surged ahead, while everyday people and small businesses fell behind.
Rushing to Contract in a Crisis
Faced with an emergency, the federal government employed unprecedented contracting authorities. In spring 2020 Congress passed the $2.2 trillion CARES Act and later nearly $5 trillion more in relief, creating programs like the Small Business PPP loans and funnels of aid to state and local governments.
At the same time, agencies invoked the Defense Production Act and emergency waivers to buy medical supplies, vaccines, and more. Operation Warp Speed, for example, promised a Manhattan-Project for vaccines. But the execution was far from transparent. Instead of standard procurement, OWS secretly routed vaccine funds through Advanced Technologies International (ATI), a defense contractor, which then paid vaccine companies directly.
The result: tens of billions in contracts hidden from public scrutiny. In fact, more than $1.9 billion went to Pfizer, $1.6 billion to Novavax, $1.8 billion to Sanofi and nearly $1 billion to Johnson & Johnson—among other deals signed in private.
As an NPR report explained, this scheme “may take a long time to unravel,” and legal experts noted that emergency speed came at the cost of accountability.
“We have to be careful about what we throw out” when suspending procurement rules, said one attorney. Yet at warp speed the normal “bible” of contracting was largely bypassed.
Aside from vaccines, literally anything labeled “COVID” could be put on a fast track. The Department of Health and Human Services, FEMA, Department of Defense and others tapped billions for ventilators, masks, tests, and therapeutics. The HHS Office of Inspector General reported that ASPR awarded 10 contracts totaling $2.9 billion to procure over 187,000 ventilators by end of 2020.
But those ventilators largely sat unused, and in some cases were never delivered. For example, New York City Comptroller Scott Stringer found the city pre-paid $8.26 million for 130 ventilators in March 2020, yet zero arrived. The vendor—a two-week-old shell company—hoarded the money, never delivered one machine, and refused to return $1.86 million of the city’s funds.
“Our investigation found that the City lost nearly $2 million on lifesaving equipment that it never received,” Stringer said in April 2021. The solution, he urged, was to “immediately restore City procurement rules to protect taxpayers from abuse by unreliable vendors”.
Similar stories played out in other states: Florida and Texas both reported huge sums spent on PPE and kits that were late or unusable. Auditors in Ohio and California flagged waste from no-bid contracts. In most cases, officials justified the shortcuts by the emergency—but critics note there was nothing unprecedented about scrutiny.
As one oversight expert asked, “Isn’t it finally time to reduce the defense budget and put more of our resources into the real national security crisis at hand?” – meaning public health.
Lobbyists, Cronies and Contracts
Many pandemic contracts went to companies with political ties. A 2024 study of UK procurement found that nearly £4.1 billion of COVID contracts went to firms with Conservative Party links.
In the U.S., one of the first contracts for masks was awarded to Prestige Ameritech, a small Illinois firm founded by a Trump supporter with no record of mass production. (Prestige later refunded the government after legal fights.) Meanwhile, 51 companies in the UK were pushed through a VIP lane—with special priority—sending £1.7 billion in orders to firms recommended by Tory ministers.
Half of that PPE turned out to be unusable. Even the UK’s health secretary admitted the system had “red flags” everywhere.
In America, watchdogs found the federal “secretary of state” for PPE was Mike Pence’s family Christmas contractor, known as HyTech, which landed two FEMA contracts totaling over $100 million. Another example: 3M, which normally did not qualify under a US defense plant list, won a special lockdown waiver to import foreign N95 masks after its domestic supplies were diverted.
Then there was a complaint about a “buy American” bias in Michigan’s mask procurement: a tiny state-run laboratory blocked U.S. companies from a $500,000 ventilator test contract, quietly giving it to China’s Huazhong. At every turn, government and industry moved quickly to shield themselves: OWS contracts to vaccine makers were exempt from Freedom of Information Act for five years.
Lobbying counts.
The Public Citizen report noted that in 2020 only 6% of COVID contractors said they lobbied, yet they got more than half the money. Firms that registered as pandemic lobbyists sent an army of 3,500 Washington operatives to the White House and Hill, and showered politicians with campaign cash.
For instance, companies that lobbied on COVID issues gave $313 million to Trump, Congress and parties from 2016–2020. It shouldn’t surprise us, then, that insiders did well. Veteran investor Richard Silberstein noted that many executives and board members of Pentagon contractors come directly from the agencies themselves.
How to break this cycle? Elizabeth Warren and others called for tough new laws. “If this report is accurate, it represents an appalling abdication of duty by [officials]… investors used early inside information… to extract enormous profits”, Warren wrote in October 2020, demanding SEC probes of suspected insider trading.
As she pointed out, even mundane announcements could ripple wealth: the plan to loan $700 million to Kodak (a Trump ally) led to frantic stock trades by well-connected investors (a case now investigated by the DOJ).
Economic studies validate these concerns. The Institute for Policy Studies and Americans for Tax Fairness documented that in spring 2020 the U.S. billionaire class grew twice as fast as federal relief paid to workers.
An Oxfam report similarly found 17 of the top 25 most profitable U.S. corporations saw roughly $85 billion more profit in 2020 than the year before. By July 2020 Oxfam warned that “the COVID-19 pandemic has exposed deep inequalities,”with “tens of millions of people… without jobs” even as “a handful of corporations are raking it in”.
Economists call this a K-shaped recovery: the rich recovered quickly and even prospered, while the poor languished. Federal data show that while the stock market (S&P 500) recovered to new highs by late 2020, tens of millions still needed unemployment aidbls.gov.
(See chart above: as corporate profits soared, the jobless rate—red dashed line—shot above 14%.) Even after trillions in pandemic spending, median incomes have barely budged compared to pre‑COVID levels, while corporate cash piles and billionaire fortunes ballooned.
Pharmaceutical and Medical Pandemic Profiteers
The pharmaceutical and medical sectors were major coronavirus profiteers. Vaccine makers and drug firms received massive government contracts—and even at fixed “no-profit” prices ended up with windfalls in overall revenues. Operation Warp Speed locked in large purchase agreements, but many details were hidden.
(One academic observed that requiring secrecy was a “bargain” that may have let drug companies reap the upside beyond the fixed payments.) For example, HHS’s BARDA program paid Gilead $20 million to develop remdesivir and later secured millions of doses at roughly $2,340 per course.
Critics noted this gave Gilead a $1.5 billion windfall as 1.5 million Americans became eligible for the drug. The government even covered Gilead’s liability against lawsuits. Meanwhile Pfizer and Moderna ultimately sold much of their vaccines at higher post-pandemic prices abroad than the U.S. paid.
Senate investigators asked why big deals—totalling about $12 billion in vaccine advance purchases—were not more transparent. (“All doses are federally owned” on paper, yet lawmaker scrutiny revealed that companies hedged their bets on liability and pricing quietly.)
Beyond vaccines, everyday medical products were gold. In 2020 the HHS strategic stockpile had to empty out billions in masks, gowns and gloves at a fraction of the purchase cost. Some companies happily dumped PPE into those contracts.
A notable case: Vivent, a tiny Canadian mask seller, landed a $130 million FEMA deal to import N95 respirators—then tried to raise the price to $500 each in August 2020 after the crisis had eased.
(FEMA refused; Vivent eventually delivered at original terms.) The Justice Department fined hundreds of pandemic price-gougers, but experts say many slipped through. Kleenex makers raised disposable-glove prices by 500% in 2020, making huge profits, while masks went from cents to dollars apiece. Congress belatedly passed a law against insider trading on pandemic briefs, but enforcement has been slow.
In fields like diagnostics and therapies, large pharma also benefited. As COVID surged, the FDA issued EUAs (emergency approvals) for new drugs and tests, and Medicare agreed to pay steeply for them. The makers of monoclonal antibodies (Regeneron, Eli Lilly) and new antivirals (Merck’s molnupiravir) secured yes/no government stockpiles at prices vastly above usual medicine costs.
In the security world, the Pentagon even floated a $10 billion plan for “COVID-19 defense” weapons (from drones to nuclear-tipped missiles) that raised eyebrows. Project On Government Oversightnoted that many top military contractors used the crisis as an excuse to ask for bailouts and relaxed oversight—even while hospitals begged for help.
POGO analysts asked: “Isn’t it finally time to reduce the defense budget and put more of our resources into the real national security crisis at hand?”. Instead, Congress increased defense spending and slipped pandemic-related add-ons into defense bills. In all, the traditional war-machine got a relative boost, while the true health agencies (NIH, CDC, FDA) remained chronically underfunded.
Big Tech and Surveillance. A less obvious corridor of profiteering was surveillance and tech services. Palantir, the data-mining firm cofounded by a Trump adviser, saw its revenue double from 2019 to 2020—thanks largely to public health contracts.
In late 2022 the CDC quietly inked a five-year $443 million contract with Palantir to consolidate the outbreak surveillance software the agency had built during the pandemic. This “Common Operating Picture” program had been put in place at Warp Speed’s height; now Palantir will get a steady flow of taxpayer dollars to run it “beyond COVID”.
Meanwhile, dozens of smaller tech vendors popped up, offering apps and drones to enforce quarantines. Clearview AI, a facial-recognition startup, boasted it could set up social-distance monitoring systems. Even Rolls Royce and private airlines bought surveillance drones to scan crowds and enforce lockdowns, then turned those tools into products for police.
These deals were often hastily negotiated—some state contracts for contact-tracing apps never worked properly. But in a crisis, fear trumps scrutiny, and surveillance companies found willing buyers in government.
Inside Stock Sales and Insider Dealing
As government officials encouraged Americans to “buy low” in March 2020, some in Congress were quietly selling. In early 2020, Senators Richard Burr (R-NC) and Kelly Loeffler (R-GA) faced ethics probes for selling millions in stock right after receiving private briefings about the virus. Burr disposed of between $628,000 and $1.7 million of shares on Feb. 13, 2020—just days after assuring the public in January that the virus was “very much under control”.
Burr later claimed he “relied only on public information,” but his actions drew a House Ethics inquiry. Senator Loeffler sold millions of dollars in stocks in January 2020 after attending a health briefing, and bought calls on a telemedicine firm two days before publicly praising the administration’s pandemic response.
A Politico analysis found that 12 Senators made 127 stock trades between Feb–Apr 2020 and dozens of House members made over 1,350 trades. Many shifted into companies expected to benefit: buying videoconference or pharmaceutical stocks, shedding travel and leisure shares.
Most of these trades were “technically legal” under the weak STOCK Act, but critics said they reek of insider advantage. Senator Warren and others demanded investigations, arguing that using nonpublic briefings to guide personal trades is the “truest textbook case of insider trading”. “This early, inside information… was used to extract enormous profits,” Warren wrote, calling it an “appalling abdication of duty” by officials.
Stock exchanges and watchdogs tracked the phenomenon: one investor noticed that shares in companies like Zoom, Moderna, and Clorox rose in tandem with sudden trading spikes by politicians’ portfolios.
A nonpartisan Campaign Legal Center report concluded that the sheer volume of Congress’s trades during the crisis “underscores the need for more transparency and ethics protections”.
In 2021 Congress finally banned members from trading individual stocks outright; but critics say it’s still an open question whether similar patterns continued in 2021-2022 relief laws (like the $700B loan program for airlines, where some CEOs were later found to be shareholders).
Small Businesses Left Out, Whistleblowers Cry Fraud
While giants feasted, smaller vendors and suppliers often found themselves blocked out. Strict procurement goals for small businesses were loosened in many states under emergency orders.
One whistleblower from a veteran-owned medical manufacturer reported that local officials accepted cheap offers from a big-league supplier with no track record while rejecting bids from the established small firm. Small respirator makers also complained that the Pentagon and FEMA set low-quality standards or opaque terms that essentially directed contracts to a few favorite companies.
Some were outright frozen out by “sole-source” emergency clauses. Contractors on the U.S. Treasury’s payroll reported that the majority of big stimulus contracts went to traditional incumbents, not minority- or women-owned businesses.
Indeed, Public Citizen found that many winners of pandemic contracts “had never worked with the government before” – but after a quick pivot their products were deemed indispensable.
Legal experts say these practices will be challenged in the courts. Already, advocacy groups have filed lawsuits over allegedly corrupt award processes: for instance, New Jersey lawyers sued to halt a $1.2 billion state-order of ventilator parts purchased through an exclusive deal with a single firm.
In Michigan, a competing supplier sued when a giant contract for protective gowns was locked in with a politically connected out-of-state bidder. And at the federal level, the Presidential COVID-19 Task Force Office has quietly opened several fraud investigations into contractors who failed to deliver on masks and tests.
Whistleblowers to the pandemic oversight commission have reported widespread overbilling; one former Defense Department official said the system was “wide open to abuse and waste.” The evidence suggests he was right. “There is no excuse not to learn from our misfires going forward,” admonished New York’s Comptroller Stringer.
Global Comparisons: Greed Knows No Borders
The story of pandemic profiteering is global. In the U.K., an inquiry by Transparency International UK found that out of £30.7 billion in COVID contracts awarded by over 400 agencies, £15.3 billion showed at least three corruption red flags.
This included 28 deals worth £4.1 billion going to companies linked to the ruling party, and eight contracts (totaling £500 million) given to shell companies only months old. One famous case involved firms owned by MPs or their associates winning PPE orders without competition.
A U.K. court later ruled that the government’s “VIP lane” procurement mechanism had been unlawful. Overall, almost two-thirds of UK COVID contracts were let without competitive bids, and public auditors later wrote off £14.9 billion in spent funds—equal to the entire NHS PPE bill. The message: when urgency met cronyism, taxpayers paid dearly.
In Brazil, vaccine procurement scandals roiled the government. In mid-2021, congressional investigators revealed that President Jair Bolsonaro’s aides were allegedly informed of a 1.6 billion-real (≈$300 million) deal to buy Bharat Biotech’s Covaxin shot from India, but did nothing as concerns of kickbacks surfaced.
A contract was suspended amid fraud allegations, and Bolsonaro’s administration ultimately declined to authorize Covaxin. Protesters in Brasília carried banners reading “COVID is killing, corruption is enriching”. Opposition senators filed criminal complaints, accusing the president of turning a blind eye to a “giant corruption scheme” in the Ministry of Health.
By year’s end, Brazil’s top health official was under investigation, and a former health minister’s son was arrested over vaccine bribery. The Covaxin affair underscored a global trend: even life-saving programs became entangled with graft.
India’s devastating second wave in 2021 also had an undercurrent of corruption. Reports by anti-graft agencies documented profiteering amid the oxygen crisis: unscrupulous middlemen hoarded supplies and sold medical oxygen and cylinder refills on black markets at extortionate pricesu4.no. Hospitals charged huge “facilitation fees” for ICU beds. State relief funds were pillaged through false invoicing.
New Delhi’s Auditor General found that pandemic contracts awarded by state governments were often in violation of procurement laws. In one state alone, a COVID hospital project budgeted at $50 million ballooned to $100 million with no documentation of where the extra funds went. Transparency activists in Mumbai and Delhi sued authorities for refusing to disclose emergency contract details. In sum, India’s second wave brought an “oxygen crisis” of both medicine and morality.
The pattern repeats in poorer countries. In South Africa, a Special Investigating Unit identified over R14.2 billion (~$1 billion) in questionable COVID procurements – from overpriced PPE to non-deliverable hygiene packsu4.no.
Even WHO-backed international vaccine programs (like COVAX) saw scandals: vaccines meant for Africa were delayed amid accusations that certain African governments diverted doses in exchange for bribes. In the United States, of course, we could afford to bungle trillions with little immediate pain in public services—but elsewhere each lost dollar meant a child unvaccinated or a life unprotected.
The Inequality Legacy
By early 2025, the net effect of these pandemic contracts is painfully clear. Top firms that secured COVID deals report record revenues, and many stock prices remain above pre-2020 levels. Lockheed Martin, Pfizer, 3M and a dozen others saw their stock bump during key moments of the crisis.
Meanwhile, wage growth for rank-and-file workers has barely kept pace with inflation, and government debt has ballooned. The pandemic accelerated a preexisting trend: concentration of wealth. As economists have noted, the U.S. billionaire class saw its fortunes grow twice as fast as the Fed paid out stimulus checks.
One third of Americans say they had trouble paying medical bills after COVID hit. Homelessness spiked in 2020-2022, even as penthouses sold for record prices.
Compounding the injustice, many pandemic contracts reinforced racial and geographic inequities. Minority communities, hardest hit by the virus, rarely got a share of the procurement bonanza. A GAO study in 2021 found that small businesses—especially those owned by women and people of color—received only a tiny fraction of COVID contracts. Federal programs like Meals on Wheels and community health centers were underfunded, while bailouts flowed to multi-state chain hotels and theaters (often owned by the well-connected).
Whistleblowers and the Fight for Oversight
Despite these entrenched interests, fierce critics and whistleblowers continue to speak out. Frontline doctors and local officials testified before Congress about how personal protective equipment from favored suppliers often failed safety tests, leaving them exposed.
Former FEMA buyers and intelligence officers leaked documents to watchdogs, showing how contract provisions were altered at the last minute to benefit crony firms. Legal experts from Public Citizen and POGO urged new reforms: tight conflict-of-interest rules, public reporting of all emergency contracts, and an excess-profits tax on companies that made outsized gains during the crisis.
(Oxfam had called for just such a tax in 2020.) Bipartisan bills proposed by Sens. Coons and Warren would create a permanent Pandemic Response Oversight Board with subpoena power; several state attorneys general have opened investigations into their own COVID spending.
Most poignantly, small business owners and taxpayers who saw their money squandered have become activists. A family-run respirator maker in Nevada filed a complaint to the DOJ after losing two mask contracts to a politically-connected middleman.
A New Jersey hospital CEO wrote op-eds demanding transparency after his county paid twice market price for N95s from a private seller. These voices say the pandemic exposed a broken procurement system: one that feeds inequality by funnelling cash to the already-rich few. As one former contract auditor put it, “We couldn’t win any of those deals. The process was rigged from the start.”
Conclusion
The COVID-19 emergency demanded speed and scale—but speed did not have to mean cronyism. A nation facing an existential threat deserves pandemic contracting that is transparent, competitive and fair. Instead, billions of taxpayer dollars flowed to insiders, enriching some of the wealthiest corporations and individuals while little trickled down to the communities most in need.
This scandal will cast a long shadow: not only has it deepened our economic divide, it has corroded trust in government. In the months and years ahead, investigators will need to fully unpack all these contracts and hold wrongdoers to account.
Washington and the states should learn from these failures by codifying stronger procurement rules, closing insider-trading loopholes, and perhaps taxing excessive pandemic windfalls. Otherwise, the next emergency will be only a license for the same pandemic profiteers to grab again from the public purse.
References: The investigation above draws on reporting and analysis from nonprofit watchdogs and the media. Key sources include an Institute for Policy Studies study on billionaire wealth, Public Citizen’s “COVID Lobbyists” report, The Guardian and Transparency International Report on UK procurement, congressional and news investigations of U.S. contracts and stock trades, and government audit reports on ventilators and city contracting failures. We also include interviews and statements from oversight officials (NYC Comptroller) and experts (Oxfam analysts, legal scholars) who have called out pandemic profiteering.
*You May Be interested in Reading this investigative piece by the same author, “Pegasus Spyware India: Exposing the Silent Crackdown on Press Freedom“.
*Learn More About The Author Here.
